MFN Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

MFN Partners’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-46,000	Closed	-$598K	–	12
2019 Q3	$598K	Hold	46,000	–	–	0.09%	14
2019 Q2	$597K	Hold	46,000	–	–	0.09%	17
2019 Q1	$725K	Hold	46,000	–	–	0.12%	15
2018 Q4	$926K	Buy	+46,000	New	+$1.01M	0.16%	15

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

MFN Partners's RVNC Position: Q4 2019 in Review

MFN Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2019, closing a stake of 46,000 shares — an estimated $598K sold.

MFN Partners first reported a position in RVNC in Q4 2018 and held it in 4 quarters. The position peaked at $926K in Q4 2018. 134 funds tracked by Wall St. Rank hold RVNC as of Q4 2019.

MFN Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
MFN Partners sold 46,000 Revance Therapeutics, Inc. shares in Q4 2019, an estimated $598K.
MFN Partners first reported a position in Revance Therapeutics, Inc. in Q4 2018 and held it in 4 quarters.
MFN Partners's Revance Therapeutics, Inc. position peaked at $926K in Q4 2018.
134 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2019.

Based on MFN Partners's 13F filing for Q4 2019, filed 13 Feb 2020.